13.05.2019
- To lighten its debt burden of more than $30 billion resulting from last year’s acquisition of Shire, Japanese pharma giant Takeda is selling Shire’s dry-eye drug Xiidra to...
06.12.2018
- Shareholders of Japanese drugmaker Takeda and Netherlands-domiciled, US-managed Shire have separately approved the merger of the two pharmaceutical manufacturers. All regulatory...
23.11.2018
- European regulators have approved Takeda’s proposed acquisition of its US rival Shire, clearing the way for the £46 billion deal to complete. The clearance is conditional on both...
01.11.2018
- Japanese drugmaker Takeda has confirmed it is talking to the European Commission about selling Shire’s inflammatory bowel disease candidate SHP647, along with some associated...
14.09.2018
- Following the completion of its $64 billion takeover of Shire, Japanese drugmaker Takeda has announced plans to restructure its US operations. In a first move, it will close its...
04.09.2018
- Ahead of its acquisition by Japan’s Takeda Pharmaceutical, Ireland-domiciled, London-listed and US-focused Shire has completed the sale of its oncology portfolio with $262 million...
11.07.2018
- On its path to acquiring Ireland-domiciled, London-listed drugmaker Shire, Japan’s Takeda Pharmaceutical has received unconditional clearance from the US Federal Trade Commission...
09.05.2018
- Takeda Pharmaceutical and Shire have finally agreed terms for a merger, ending a takeover battle that has seen the Japanese drugmaker bid five times since late March for the...
